diazepam has been researched along with Parkinsonian Disorders in 6 studies
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.
diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone." | 5.34 | Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. ( Cansel, N; Herken, H; Ozen, ME; Savas, HA; Yumru, M, 2007) |
| " Following postoperative recovery, we recorded sleep for 6h, induced anesthesia 24h later using ketamine/diazepam or pentobarbital, and repeated sleep recordings sessions 48h and 6days later." | 3.81 | Impact of anesthetic regimen on the respiratory pattern, EEG microstructure and sleep in the rat model of cholinergic Parkinson's disease neuropathology. ( Ciric, J; Kalauzi, A; Lazic, K; Petrovic, J; Saponjic, J, 2015) |
| "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone." | 1.34 | Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. ( Cansel, N; Herken, H; Ozen, ME; Savas, HA; Yumru, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kan, HL | 1 |
| Tung, CW | 1 |
| Chang, SE | 1 |
| Lin, YC | 1 |
| O'Connor, KA | 2 |
| Mahoney, E | 1 |
| Ramirez-Zamora, A | 2 |
| Molho, ES | 1 |
| Pilitsis, JG | 2 |
| Shin, DS | 2 |
| Lazic, K | 1 |
| Petrovic, J | 1 |
| Ciric, J | 1 |
| Kalauzi, A | 1 |
| Saponjic, J | 1 |
| Feustel, PJ | 1 |
| Molho, E | 1 |
| Ukley, B | 1 |
| Hermann, W | 1 |
| Ozen, ME | 1 |
| Yumru, M | 1 |
| Savas, HA | 1 |
| Cansel, N | 1 |
| Herken, H | 1 |
6 other studies available for diazepam and Parkinsonian Disorders
| Article | Year |
|---|---|
In silico prediction of parkinsonian motor deficits-related neurotoxicants based on the adverse outcome pathway concept.
Topics: Adverse Outcome Pathways; Animals; Diazepam; Electron Transport Complex I; Molecular Docking Simulat | 2022 |
Effect of diazepam and yohimbine on neuronal activity in sham and hemiparkinsonian rats.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Diazepam; Motor Activity; Neurons; Parkinsonian Dis | 2017 |
Impact of anesthetic regimen on the respiratory pattern, EEG microstructure and sleep in the rat model of cholinergic Parkinson's disease neuropathology.
Topics: Adjuvants, Anesthesia; Anesthesia; Anesthetics; Animals; Brain; Diazepam; Electrocorticography; Elec | 2015 |
Investigation of diazepam efficacy on anxiety-like behavior in hemiparkinsonian rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Diazepam; Exploratory Behavior; Functional Laterali | 2016 |
[Subacute Parkinson's disease after suicide attempt with diazepam].
Topics: Adult; Antiparkinson Agents; Cerebellum; Diazepam; Disease Progression; Drug Overdose; Follow-Up Stu | 2013 |
Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
Topics: Adult; Antipsychotic Agents; Biperiden; Diagnosis, Differential; Diazepam; Drug Therapy, Combination | 2007 |